乔志卿,卜军,丁嵩,宋玮,杜勇平,沈节艳,金叔宣,幺天保,何奔

• 1:上海交通大学医学院附属仁济医院心内科

摘要(Abstract)：

目的探讨急性ST段抬高性心肌梗死(STEMI)急诊经皮冠状动脉介入治疗(PCI)时冠状动脉内应用维拉帕米对冠状动脉灌注、心肌灌注及临床预后的影响。方法本研究为前瞻性、随机、双盲、对照性临床研究。连续性入选99例STEMI拟行急诊PCI的患者,随机分为维拉帕米组与对照组。在支架释放后即刻,维拉帕米组在靶血管内注入维拉帕米200μg,对照组在靶血管内注入肝素生理盐水,比较两组PCI术前、术后和冠状动脉内注药后的冠状动脉灌注和心肌灌注的差别。冠状动脉灌注以心外膜TIMI血流(TFG)和校正的TIMI血流帧数计数(CTFC)来评价。心肌灌注以TIMI心肌灌注分级(TMPG)和心肌灌注显影(MBG)来评价。并比较两组在PCI术后1周心脏彩色超声结果、住院期间以及随访期间主要心脏不良事件(MACE)发生率上的差别。结果最终91例患者有完整资料,其中维拉帕米组47例,对照组44例,两组临床基本特征和造影特征相仿。维拉帕米组和对照组在术前和支架释放后即刻冠状动脉灌注和心肌灌注各指标差异均无统计学意义(P>0.05)。冠状动脉内注入维拉帕米后,维拉帕米组的CTFC、TFG、MBG、TMPG均较对照组有显著改善,分别为CTFC:27.1±14.2比39.0±23.8,P=0.011;TFG≥2级:100%比90.9%,P=0.035;MBG≥2级:91.5%%比75.5%,P=0.034;TMPG≥2级:89.4%比72.7%,P=0.042。维拉帕米组和对照组PCI术后1周时左室射血分数(63.4%±8.2%比63.5%±10.3%,P=0.578)、院内MACE发生率(4.3%比9.1%,P=0.613)和3个月MACE发生率(23.9%比22.7%,P=0.894)差异均无统计学意义。结论STEMI患者急诊行PCI治疗时,冠状动脉内应用维拉帕米可显著改善冠状动脉灌注和心肌灌注水平,但未观察到其对急诊PCI术后心室重构和短期临床预后的显著影响。

关键词(KeyWords)： 维拉帕米;心肌梗死;血管成形术,经腔,经皮冠状动脉;心肌再灌注

Abstract:

Keywords:

基金项目(Foundation): 上海市优秀学科带头人基金(35508XD14026);; 上海市科委登高重点课题(064119501);; 浦东新区重大协作课题(PW2006D-3)

作者(Author): 乔志卿,卜军,丁嵩,宋玮,杜勇平,沈节艳,金叔宣,幺天保,何奔

参考文献(References)：

• [1]Assali AR,Sdringola S,Ghani M,et al.Intracoronary adenosineadmininstered during pereutaneous intervention in acute myocar-dial infarction and reduction in the incidence of"no reflow"phe-nomenon.Catheter Cardiovasc Interv,2000,51:27-31.
• [2]Gibson CM,Cannon CP,Murphy SA,et al.for the TIMI studygroup.Relationship of TIMI myocardial perfusion grade to mortal-ity after administration of thrombolytic drugs.Circulation,2000,101:125-130.
• [3]Porto I,Ashar V,Mitchell ARJ,et al.Pharmacological Manage-ment of No Reflow During Percutaneous Coronary Intervention.Current Vascular Pharmacology,2006,4:95-100.
• [4]Vijayalakshmi K,Ashton V,Wright R,et al.Corrected TIMIframe count(cTFC):applicability in modern digital catheter la-boratories when different frame acquisition rates are used.Cathe-ter Cardiovasc Interv,2004,63:426-432.
• [5]The TIMI Study Group.The Thrombolysis in Myocardial Infarc-tion(TIMI)trial.N Engl J Med,1985,312:932-936.
• [6]Gibson CM,Cannon CP,Daley WL,et al.TIMI frame count:aquantitative method of assessing coronary artery flow.Circula-tion,1996,93:879-888.
• [7]Gibson,CM,Murphy,SA,Rizzo,MJ,et al.Relationship be-tween TIMI frame count and clinical outcomes after thrombolyticadministration.Thrombolysis In Myocardial Infarction.(TIMI)Study Group.Circulation,1999,99:1945-1950.
• [8]van't Hof AWJ,Liem A,Suryapranata H,et al.Angiographicassessment of myocardial reperfusion in patients treated with pri-mary angioplasty for acute myocardial infarction:myocardialblush grade:Zwolle Myocardial Infarction Study Group.Circula-tion,1998,97:2302-2306.
• [9]何奔,丁嵩,卜军,等.脑利钠肽和C反应蛋白在急性冠状动脉综合征介入治疗患者的预后价值.中华心血管病杂志,2006,34:349-352.
• [10]Nagata Y,Usuda K,Uchiyama A,et al.Characteristics of thepathological images of coronary artery thrombi according to the in-farct-related coronary artery in acute myocardial infarction.Circ J,2004,68:308-314.
• [11]Fischell TA.Pharmaceutical interventions for the management ofno-reflow.J Invasive Cardiol,2008,20:374-379.
• [12]Mamas MA,Fraser D,Fath-Ordoubadi F.The role of thrombec-tomy and distal protection devices during percutaneous coronaryinterventions.Euro Interv,2008,4:115-123.
• [13]Chi-Ling Hang,Cha-Ping Wang,Hon-Kan Yip,et al.Early Ad-ministration of Intracoronary Verapamil Improves Myocardial Per-fusion During Percutaneous Coronary Interventions for Acute Myo-cardial Infarction.Chest,2005,128:2593-2598.
• [14]Vijayalakshmi K,Whittaker VJ,Kunadian B,et al.Prospec-tive,randomised,controlled trial to study the effect of intracoro-nary injection of verapamil and adenosine on coronary blood flowduring percutaneous coronary intervention in patients with acutecoronary syndromes.Heart,2006,92:1278-1284.
• [15]Ross AM,Gibbons RJ,Stone GW,et al.Arandomized,double-blinded,placebo-controlled multicenter trial of adenosine as anadjunct to reperfusion in the treatment of acute myocardial infarc-tion(AMISTAD-Ⅱ).J Am Coll Cardiol,2005,45:1775-1780.